吉利德科学Gilead Sciences (GILD) 2013年年度报告「NASDAQ」.pdf

1、ANNUAL REPORT 2013GileadGilead Sciences,Inc.333 Lakeside Drive Foster City,California 94404650 574 3000 T 800 445 3235650 578 9264 FThe approval and introduction of Sovaldi as a treatment for chronic hepatitis C virus(HCV)infection stands out among Gileads 2013 accomplishments.For millions of people

2、 living with HCV,Sovaldi-based therapy may offer a cure with a significantly shorter and less burdensome course of treatment.Gilead also advanced new HIV products and research during the past year and made significant progress in oncology,the companys newest therapeutic area of focus.Fueled by stron

3、g commercial performance,Gileads financial position is stronger than ever,with record total revenues in 2013 of$11.2 billion.Each of the milestones and accomplishments of the past year exemplify Gileads mission of developing and delivering medicines that redefine how serious diseases are treated.Our

4、 accomplishments also exemplify the dedication of Gileads 6,000 employees,who collaborate with the medical community,partners and each other to understand and to pursue whats in the best interest of patients.A New Era in Hepatitis C Treatment,Continued Focus on Liver DiseasesOn December 6,Sovaldi,a

5、once-daily nucleotide analog polymerase inhibitor for the treatment of chronic HCV infection,was approved by the U.S.Food and Drug Administration(FDA)as a component of a combination antiviral treatment regimen.This milestone is the culmination of many years of workdeveloping the molecule,designing c

6、linical trials to best define its use across various genotypes and patient populations,and ensuring involve-ment of the medical community,which has long awaited a new treatment.In addition,Gilead worked quickly to build an experi-enced commercial and medical affairs organization prepared to support